https://www.baskingbiosciences.com https://www.baskingbiosciences.com/about https://www.baskingbiosciences.com/science https://www.baskingbiosciences.com/programs https://www.baskingbiosciences.com/publications https://www.baskingbiosciences.com/news https://www.baskingbiosciences.com/contact-us https://www.baskingbiosciences.com/news-releases/basking-biosciences-announces-close-of-55-million-financing-to-accelerate-clinical-development-for-first-reversible-thrombolytic-for-ischemic-stroke https://www.baskingbiosciences.com/news-releases/basking-biosciences-announces-first-participants-dosed-in-phase-1-study-of-bb-025-a-direct-acting-reversal-agent-for-investigational-stroke-therapy-bb-031 https://www.baskingbiosciences.com/news-releases/basking-biosciences-doses-first-patients-in-part-b-of-phase-2-stroke-trial-unlocks-27-5-million-financing-tranche-and-appoints-julia-c-owens-ph-d-as-chief-executive-officer https://www.baskingbiosciences.com/news-releases/basking-biosciences-doses-first-patients-in-phase-2-clinical-trial-of-reversible-thrombolytic-bb-031-for-acute-ischemic-stroke https://www.baskingbiosciences.com/news-releases/basking-biosciences-inc-completes-5-4m-seed-financing https://www.baskingbiosciences.com/news-releases/basking-biosciences-presents-positive-clinical-results-from-safety-and-dose-escalation-study-for-first-reversible-thrombolytic-agent-at-isc-2023 https://www.baskingbiosciences.com/news-releases/basking-biosciences-to-present-clinical-trial-results-on-first-reversible-thrombolytic-agent-at-american-heart-association-international-stroke-conference-2023 https://www.baskingbiosciences.com/legal/privacy-policy https://www.baskingbiosciences.com/legal/terms-of-use